Results 31 to 40 of about 25,087 (209)

Erythematous Macular Eruption in an Older Woman [PDF]

, 2019
A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil, McLaughlin, David, Tauro, Sudhir   +2 more
core   +2 more sources

Zebrafish Model of MLL-Rearranged Acute Myeloid Leukemia [PDF]

, 2020
Background: Acute myeloid leukemia (AML) is the second most common type of leukemia. Standard treatment includes chemotherapy as well as stem cell transplantation, but for aging patients and those with impaired immune function these rigorous therapies ...
Belt, Alex, Corey, Seth J., Grant, Steven, Rothschild, Sarah C., Tombes, Robert M.   +4 more
core   +1 more source

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax [PDF]

, 2018
Fluorizoline is a new synthetic molecule that induces apoptosis by selectively targeting prohibitins. In the study herein, the pro-apoptotic effect of fluorizoline was assessed in 34 primary samples from patients with chronic lymphocytic leukemia ...
Albericio Palomera, Fernando, Banda, Esmeralda de la, Cosialls Castel, Ana Mª, Gil i Santano, Joan, González Barca, Eva, González Gironés, Diana M., Iglesias i Serret, Daniel, Lavilla Grífols, Rodolfo, Núñez-Vázquez, Sonia, Pomares, Helena, Pons i Irazazábal, Gabriel, Preciado Gallego, Sara, Saura-Esteller, José   +12 more
core   +1 more source

Biological aspects of mTOR in leukemia [PDF]

, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp, Gianfelici, V, Mirabilii, S, Piedimonte, M, Ricciardi, Mr, Tafuri, A.   +5 more
core   +1 more source

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy [PDF]

, 2017
BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anti-cancer targets. Using small cell lung cancer (SCLC) as a model, we demonstrated the presence of differential addiction of cancer cells to anti-apoptotic BCL-2, BCL-
Chen, Hui-Chen, Cheng, Emily H, Dong, Yiyu, Ganesan, Yogesh Tengarai, Han, Song, Hellmann, Matthew D, Hsieh, James J, Inoue-Yamauchi, Akane, Ishizawa, Kota, Jebiwott, Sylvia, Jeng, Paul S, Kim, Kwanghee, Kris, Mark G, Pietanza, Maria C   +13 more
core   +2 more sources

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. [PDF]

, 2015
TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We
Amstislavskiy, V., Badarinarayan, N., Bartram, T., Baruchel, A., Basso, G., Borkhardt, A., Bornhauser, B., Bourquin, J.P., Canpolat, C., Cario, G., Cavé, H., Dakaj, D., Delorenzi, M., Dobay, M.P., Eckert, C., Ellinghaus, E., Eugster, S., Fischer, U., Forster, M., Franke, A., Frismantas, V., Ginzel, S., Gombert, M., Haas, O.A., Heidenreich, O., Hemmrich-Stanisak, G., Hezaveh, K., Hornhardt, S., Husemann, P., Höll, J.I., Kachroo, P., Korbel, J.O., Kratsch, C., Kratz, C.P., Kronnie, G.T., Lehrach, H., Marovca, B., McHardy, A.C., Moorman, A.V., Niggli, F., Panzer-Grümayer, R., Petersen, B.S., Raeder, B., Ralser, M., Rinaldi, A., Risch, T., Rosenstiel, P., Schrappe, M., Schreiber, S., Schäfer, D., Schütte, M., Stade, B., Stanulla, M., Stütz, A.M., Sultan, M., Sungalee, S., Tchinda, J., Thiele, R., Vora, A., Warnatz, H.J., Weid, N.v., Worth, C.L., Yaspo, M.L., Zaliova, M., Zhang, L., Zichner, T., Zimmermann, M.   +66 more
core   +1 more source

Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine. [PDF]

Cancer
Abstract Background Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency impairs cellular redox balance through reduced NADPH production and is the most common enzymatic disorder‐causing anemia. Venetoclax combined with azacitidine (Ven‐Aza) targets leukemic stem cells by disrupting oxidative phosphorylation and inducing mitochondrial stress. This study
Buchrits S, Rozental A, Korngold N, Algor O, Partouche S, Granot G, Raanani P, Wolach O.   +7 more
europepmc   +2 more sources

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine

Cell Death and Disease
Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges.
Mahesh Tambe, Sarah Unterberger, Mette C. Kriegbaum, Ida Vänttinen, Ezgi June Olgac, Markus Vähä-Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman   +8 more
doaj   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Hematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla   +3 more
doaj   +1 more source

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management. Methods A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐
Zhijuan Liu, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng, Yunpeng Dai, Lian Jiang, Lirong Sun, Xiaowen Zhai, Rong Liu, Chunju Zhou, Zifen Gao, Yonghong Zhang, Xiaomei Yang   +20 more
wiley   +1 more source